α-1 and α-2 Adrenergic Antagonists Relieve Thermal Hyperalgesia in Experimental Mononeuropathy from Chronic Constriction Injury

Phentolamine, a nonspecific α1- and α2-adrenergic antagonist, relieves pain in patients with reflex sympathetic dystrophy. We sought to determine whether phentolamine, prazosin (α1 antagonist), or SKF86466 (α2 antagonist) relieve thermal hyperalgesia in rats with neuropathic pain. Four days after pr...

Full description

Saved in:
Bibliographic Details
Published inAnesthesia and analgesia Vol. 92; no. 6; pp. 1558 - 1562
Main Authors Hord, Allen H, Denson, Donald D, Stowe, Barry, Haygood, Robert M
Format Journal Article
LanguageEnglish
Published Hagerstown, MD International Anesthesia Research Society 01.06.2001
Lippincott
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Phentolamine, a nonspecific α1- and α2-adrenergic antagonist, relieves pain in patients with reflex sympathetic dystrophy. We sought to determine whether phentolamine, prazosin (α1 antagonist), or SKF86466 (α2 antagonist) relieve thermal hyperalgesia in rats with neuropathic pain. Four days after producing a chronic constriction injury (CCI), thermal hyperalgesia was tested by measuring paw withdrawal latency (PWL). After injection of phentolamine, prazosin, or SKF86466 each at doses of 1, 2, or 5 mg/kg, PWL tests were measured at 5 min and repeated at 15-min intervals for 1 h. Phentolamine, prazosin, and SKF86466 1, 2, and 5 mg/kg provided statistically significant analgesia in rats with CCI for at least 65 min. PWL did not return to baseline levels after 1 or 2 mg/kg of prazosin or SKF86466 but did so after 35 min after phentolamine 2 mg/kg. After 5 mg/kg, PWL returned to preoperative values between 5 and 50 min for phentolamine, at 35 and 65 min for prazosin, and at 50 min for SKF86466. We conclude that both α1 and α2 peripheral receptors of the sympathetic nervous system are involved in the thermal hyperalgesia caused by CCI and that thermal hyperalgesia can be reversed by both α1 and α2 antagonists in a dose-dependent manner.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0003-2999
1526-7598
DOI:10.1097/00000539-200106000-00042